Role of Diet and Exercise in the Management of NAFLD
AASLD LiverLearning®, Dr. Michelle Long & Dr. Monica Konerman, 214223
The Cost-Effective Approach to Evaluationof Abnormal Liver Enzymes
AASLD LiverLearning®, Elliot Tapper, 213386
Histopathology of granulomatous liver disease
AASLD LiverLearning®, Jason Lewis, 212276
Early liver transplantation for severe alcoholic hepatitis
AASLD LiverLearning®, Gene Im, 212277
Pro: Patient and allograft survival remain the best metric to gauge successful liver transplantation
AASLD LiverLearning®, John F. Renz, 212278
The link between hepatitis C virus and diabetes mellitus: Improvement in insulin resistance after eradication of hepatitis C virus
AASLD LiverLearning®, Justine Hum, 212279
Transplantation: Loyola university (Con) patient and graft survival outcome at 1 and 3 years posttransplant do not reflect the value of successful liver transplantation
AASLD LiverLearning®, Eric Kallwitz, 212280
Hepatitis C: Who should treat hepatitis C virus? The role of the primary care provider
AASLD LiverLearning®, Tram Tran, 212281
Surgical Risk in the Portal Hypertensive Patient
AASLD LiverLearning®, Prof. Lawrence S. Friedman & Manuel I. Rodriguez-Davalos, 209972
Clinical Liver Disease: Introducing hot topics in hepatology
AASLD LiverLearning®, AASLD, 212270
Role of alcohol in nonalcoholic steatohepatitis: Rush university (Con) patients with nonalcoholic steatohepatitis should be abstinent from alcohol use
AASLD LiverLearning®, Sheila Eswaran, 212271
Problematic lesions in cirrhosis
AASLD LiverLearning®, Alessandro Furlan, 212272
Health literacy and liver disease
AASLD LiverLearning®, Nikolaos Pyrsopoulos, 212273
Pro: Moderate alcohol use is beneficial in nonalcoholic steatohepatitis
AASLD LiverLearning®, Mauricio Lisker, 212274
Arresting frailty and sarcopenia in cirrhosis: Future prospects
AASLD LiverLearning®, Hui-Wei Chen, 212275
Acute on Chronic Liver Failure in Children
AASLD LiverLearning®, Prof. Simon Horslen & Dr. Akash Deep, 208050
Imaging features of hepatic arterial and venous flow abnormalities
AASLD LiverLearning®, Vincent Mellnick, 206009
Clinical studies investigating the effect of vitamin E therapy in patients with NASH
AASLD LiverLearning®, Sebastian Larion, 206010
Review of hepatobiliary contrast agents: Current applications and challenges
AASLD LiverLearning®, Alex Frydrychowicz, 206011
Fontan‐associated liver disease: Monitoring progression of liver fibrosis
AASLD LiverLearning®, Tamir Diamond, 206012
Intra‐arterial locoregional therapy in the management of hepatocellular carcinoma
AASLD LiverLearning®, Anil Seetharam, 206013
Risk factors for progression of and treatment options for NAFLD in children
AASLD LiverLearning®, Phillipp Hartmann, 206014
Use of proton pump inhibitors in chronic liver diseases
AASLD LiverLearning®, Raymond Chung, 206003
Evaluation and management of acute and chronic portal vein thrombosis in patients with cirrhosis
AASLD LiverLearning®, Kellie Young MD, 206004
Management of nosocomial spontaneous bacterial peritonitis: A complex and moving target
AASLD LiverLearning®, Amy G. Ogurick, 206005
Medication nonadherence in liver transplantation
AASLD LiverLearning®, Maureen Whitsett, 206006
A2 liver transplantation across the ABO barrier: Increasing options in the donor pool?
AASLD LiverLearning®, Jin Ge, 206007
Congestive hepatopathy: Differentiating congestion from fibrosis
AASLD LiverLearning®, Alexander Lemmer, 206008
Module 3: Current Management of Portal Hypertension and Variceal Bleeding
AASLD LiverLearning®, Juan G Abraldes, 154427
Module 2: Natural History of Cirrhosis and Management of Compensated Cirrhosis
AASLD LiverLearning®, Guadalupe Garcia-Tsao, 154428
Module 8: Pulmonary Complications in Patients with Cirrhosis
AASLD LiverLearning®, Michael Fallon, 154429
Module 2: Natural History of Cirrhosis and Management of Compensated Cirrhosis (Spanish Version)
AASLD LiverLearning®, Guadalupe Garcia-Tsao, 154430
Module 6: Hepatic Encephalopathy
AASLD LiverLearning®, Jasmohan Bajaj, 154431
Module 7: Bacterial Infections in Cirrhosis with a Focus on Spontaneous Bacterial Peritonitis
AASLD LiverLearning®, Puneeta Tandon, 154432
Module 4: Ascites
AASLD LiverLearning®, Florence Wong, 154433
Module 9: Does My Patient with Cirrhosis Need to be Referred for Liver Transplant?
AASLD LiverLearning®, Paul Martin, 154434
Module 1: Does My Patient Have Cirrhosis?
AASLD LiverLearning®, Patrick Kamath, 154435
Module 5: Hyponatremia and Hepatorenal Syndrome
AASLD LiverLearning®, Thomas Boyer, 154436
Module 3: Current Management of Portal Hypertension and Variceal Bleeding (Spanish Version)
AASLD LiverLearning®, Juan G Abraldes, 154437
Module 1: Hepatitis C Epidemiology and Prevention Globally and for the United States
AASLD LiverLearning®, John Ward, 154442
Module 2: My Patient has Tested Positive for Hepatitis C
AASLD LiverLearning®, Nancy Reau, 154443
Module 3: Assessing severity of liver disease in HCV
AASLD LiverLearning®, Jordan Feld, 154444
Module 4: Management of the Patient with Chronic HCV
AASLD LiverLearning®, Sanjeev Arora, 154445
Module 5: Management of the Chronic HCV Patient with Comorbid and Other Conditions
AASLD LiverLearning®, Raymond Chung, 154446
Module 6: Antiviral treatment of the patient with HCV infection
AASLD LiverLearning®, Michael Fried, 154447
Module 7: Management of Patients with HCV who Have Achieved a Virological
AASLD LiverLearning®, Andrew Muir, 154448
Module 8: The Pediatric patient with HCV
AASLD LiverLearning®, Kathleen Schwarz, 154449
Module 1: HBV: Epidemiology and Screening
AASLD LiverLearning®, Marc Ghany, 154457
Module 2: Patient with positive Hepatitis B serologies
AASLD LiverLearning®, Tram Tran, 154458
Module 3: Natural history of HBV and identification of treatment candidates
AASLD LiverLearning®, Norah Terrault, 154459
Module 4: Management of the Chronic HBV patient with co-morbid and other conditions
AASLD LiverLearning®, Marion Peters, 154460
Module 5: Antiviral treatment of the Patient with Chronic HBV
AASLD LiverLearning®, Anna Lok, 154461
Module 6: Prevention of HBV infection
AASLD LiverLearning®, Brian McMahon, 154462
Module 7: Hepatitis B in the Pediatric Patient
AASLD LiverLearning®, Maureen Jonas, 154463
FOLD - Unit 3: Cirrhosis
AASLD LiverLearning®, AASLD, 193367
FOLD - Unit 1: Hepatitis B
AASLD LiverLearning®, AASLD, 193371
FOLD - Unit 2: Hepatitis C
AASLD LiverLearning®, AASLD, 193373
FOLD - Unit 3: Cirrhosis - Send emails
AASLD LiverLearning®, AASLD, 217868
FOLD - Unit 1: Hepatitis B - Send emails
AASLD LiverLearning®, AASLD, 217869
FOLD - Unit 2: Hepatitis C - Send emails
AASLD LiverLearning®, AASLD, 217870
The gut microbiome and nonalcoholic fatty liver disease
AASLD LiverLearning®, Brian Nadeau, 203819
Primary sclerosing cholangitis: Unique aspects of disease in children
AASLD LiverLearning®, Jillian M. Cotter, 203820
ABO‐incompatible liver transplantation: Is it a viable option with modern innovation?
AASLD LiverLearning®, Abbas Rana, 203821
Pathological patterns of biliary disease
AASLD LiverLearning®, Jason Lewis, 203822
Nonobese nonalcoholic fatty liver disease
AASLD LiverLearning®, sammy saab, 203823
Drug‐drug interactions in hepatitis C virus treatment: Do they really matter?
AASLD LiverLearning®, Paul Kwo, 203824
Controversies in hepatitis C therapy: Reactivation of hepatitis B virus
AASLD LiverLearning®, Michael Fried, 203451
HCV treatment in patients with decompensated liver disease
AASLD LiverLearning®, Elizabeth C. Verna, 203452
Substance use disorders before and after liver transplantation
AASLD LiverLearning®, Jason L. Eccleston, 203453
Nonsurgical options for localized hepatocellular carcinoma
AASLD LiverLearning®, John Willy Haukeland, 203454
Normothermic machine perfusion of the liver
AASLD LiverLearning®, CORRESPONDENCE Garrett R. Roll, 203455
Small‐for‐size syndrome in LT
AASLD LiverLearning®, Taizo Hibi, 203456
Clinical  Hepatology Debrief
AASLD LiverLearning®, Kris Kowdley, 202145
Clinical  Hepatology Debrief: Introduction
AASLD LiverLearning®, Michael Fried, 202146
NAFLD Debrief
AASLD LiverLearning®, Kymberly Watt, 202143
NAFLD Debrief: Introduction
AASLD LiverLearning®, Michael Fried, 202144
Hepatitis Debrief
AASLD LiverLearning®, Paul Kwo, 202141
Hepatitis Debrief: Introduction
AASLD LiverLearning®, Michael Fried, 202142
Leon Schiff SOA: Acute on Chronic Liver Failure
AASLD LiverLearning®, Patrick Kamath, 202139
Leon Schiff SOA: Acute on Chronic Liver Failure: Introduction
AASLD LiverLearning®, Guadalupe Garcia-Tsao, 202140
Mayo Spheroid Reservoir Bio-Artificial Liver Improves Survival and Promotes Liver Regeneration in Post Hepatectomy ALF Pigs
AASLD LiverLearning®, Harvey Chen, 201444
Chemical and Toxicology Analysis of Ayurvedic and Herbal Drugs Causing Severe Liver Injury
AASLD LiverLearning®, Cyriac Philips, 201445
Evaluation of spheroid reservoir bioartificial liver with porcine hepatocytes in rhesus monkey model of acute liver failure
AASLD LiverLearning®, YI LI, 201446
Development of a new inhibitory antibody for prevention of HCV infection
AASLD LiverLearning®, Ken Okai, 201447
Human stem cell-derived Encapsulated Mature Liver Tissue as an effective, consistent, and durable in vitro tool for drug testing and development
AASLD LiverLearning®, Massimiliano Paganelli, 201448
The Frequency of Herbal and Dietary Supplement Mislabeling: Experience of the Drug Induced Liver Injury Network
AASLD LiverLearning®, Victor Navarro, 201449
Postgraduate Course 2017
AASLD LiverLearning®, Session Speakers, 206302
Postgraduate Course 2017 - Send emails
AASLD LiverLearning®, Session Speakers, 217875
HCV Patient Populations With Challenging Treatment Decisions
AASLD LiverLearning®, Paul Pockros, 202138
Ultrasound-based Elastography for NAFLD
AASLD LiverLearning®, Laurent Castera, 202132
New HCV Therapies in 2017 and Their Impact on Treatment Strategies
AASLD LiverLearning®, Paul Kwo, 202137
Global Perspectives on HCV Eradication
AASLD LiverLearning®, Philippa Easterbrook, 202136
Magnetic Resonance Elastography for NAFLD
AASLD LiverLearning®, Rohit Loomba, 202131
From the AASLD-IDSA Guidance Committee: How We Make Our Recommendations, What Important Gaps Remain in the Care of HCV Patients?
AASLD LiverLearning®, Susanna Naggie, 202135
HCV 2017 Treatment Symposium: Program Chair
AASLD LiverLearning®, Andrew Muir, 202133
Assessing Severity of Portal Hypertension and Prognosis
AASLD LiverLearning®, Massimo Pinzani, 202130
How Accurate is the Diagnosis of Cirrhosis?
AASLD LiverLearning®, Sumeet Asrani, 202129
AASLD/EASL Symposium: Non-invasive Assessment of Liver Disease: Program Chair
AASLD LiverLearning®, Jayant Talwalkar, 202127
Global Forum: The Global Burden of Non-alcoholic Fatty Liver Disease: Closing Remarks
AASLD LiverLearning®, Zobair Younossi, 202124
NAFLD in Children: A Global Perspective
AASLD LiverLearning®, Miriam Vos, 202123

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings